Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanggan Granule is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Good doctor Panxi Sichuan Pharmaceutical. It is primarily indicated for the treatment of influenza-like illness (ILI) and upper respiratory tract infections, specifically those characterized by the 'wind-heat' syndrome in TCM theory. The formulation is a complex mixture of herbal extracts, typically including *Isatis tinctoria* (Ban Lan Gen), *Lonicera japonica* (Jin Yin Hua), *Forsythia suspensa* (Lian Qiao), and *Artemisia annua* (Qing Hao). These components are traditionally recognized for their heat-clearing, detoxifying, and antiviral properties. Clinical studies, including randomized controlled trials, have evaluated its efficacy and safety in pediatric populations, often comparing it to standard antiviral treatments like ribavirin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kanggan Granule.